Friday, July 10, 2026

Drug profile · INN

hydroxyprogesterone caproate

hydroxyprogesterone caproate (HYDROXYPROGESTERONE CAPROATE) is a progesterone receptor agonist. Route of administration: intramuscular. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — hydroxyprogesterone caproate
US status
approved
Class
Route
INTRAMUSCULAR
Patents
0
Programs
0
Data quality
0.84

Quick answer

hydroxyprogesterone caproate (HYDROXYPROGESTERONE CAPROATE) is a progesterone receptor agonist. Route of administration: intramuscular. Current US regulatory status: approved.

Key facts

INN hydroxyprogesterone caproate
Brand HYDROXYPROGESTERONE CAPROATE
Mechanism Progesterone receptor agonist
Target Progesterone receptor
Route INTRAMUSCULAR
Formulation INJECTABLE

Mechanism of action

Progesterone receptor agonist

Primary target: Progesterone receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. desogestrel Progesterone receptor agonist
  2. medroxyprogesterone acetate Progesterone receptor agonist
  3. megestrol acetate Progesterone receptor agonist
  4. norethindrone Progesterone receptor agonist
  5. norethindrone acetate Progesterone receptor agonist
  6. progesterone Progesterone receptor agonist

Frequently asked questions

What is hydroxyprogesterone caproate?

hydroxyprogesterone caproate (HYDROXYPROGESTERONE CAPROATE) is a progesterone receptor agonist. Route of administration: intramuscular. Current US regulatory status: approved.

What is the brand name for hydroxyprogesterone caproate?

HYDROXYPROGESTERONE CAPROATE is a marketed brand name for hydroxyprogesterone caproate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of hydroxyprogesterone caproate?

hydroxyprogesterone caproate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.